RLY-1013

N/A

Report date: 2025/02/08 17:26:14
NME

Base Information

Drug NameRLY-1013
Drug Alias NameRLY-1013
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEstrogen receptor alpha degraders
TargetsEstrogen receptor alpha
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRelay Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRelay Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A